Skip to main content
Erschienen in: Current Treatment Options in Gastroenterology 2/2018

28.04.2018 | Liver (J Bajaj, Section Editor)

Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments

verfasst von: Silvia Nardelli, MD, Lorenzo Ridola, MD, PhD, Stefania Gioia, MD, Oliviero Riggio, Prof, MD, PhD

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome that occurs in up to 30% of patients with cirrhosis. HE may be a consequence of pure liver failure, as in patients with fulminant hepatitis, or of the combination of liver failure and portal-systemic shunting, as in patients with liver cirrhosis. Episodes of HE are usually related to precipitating events, such as infections or gastrointestinal bleeding; a minority of cirrhotic patients experienced a chronic HE, refractory to standard medical treatment. The prevention of HE recurrence, after the first episode of HE, could be obtained by the administration of prophylactic therapy with lactulose, rifaximin or a combination of both.
The aim of this review is to clarify some key points in the management of cirrhotic patients with HE, not responsive to first line treatment.

Recent findings

Recent studies investigated the role of fecal microbiota transplantation in the treatment of HE with promising results, but further investigations are needed.

Summary

In a cirrhotic patient with acute cognitive impairment, the correct diagnosis of HE, after excluding other causes of neurological diseases, is mandatory for the correct management of the precipitating factors and for the treatment. In patients not responsive to standard treatment, the probable precipitating factors have not been correctly identified, multiple precipitating events are coexisting or a new precipitating event is superimposed.
In some patients with recurrent HE, characterized by persistent alterations in neurological symptoms, without specific precipitants events, the presence of spontaneous or iatrogenic shunts should be investigated.
Literatur
1.
Zurück zum Zitat Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325–36.PubMedCrossRef Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325–36.PubMedCrossRef
2.
Zurück zum Zitat •• Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35. These International practice guidelines could be very useful for practitioners in the management of patients with HEPubMedCrossRef •• Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35. These International practice guidelines could be very useful for practitioners in the management of patients with HEPubMedCrossRef
3.
Zurück zum Zitat • Riggio O, Nardelli S, Gioia S, Lucidi C, Merli M. Management of hepatic encephalopathy as an inpatient. Clinical Liver Disease. 2015;5(3):79–82. This paper could be useful to guide physicians in differential diagnosis of HECrossRef • Riggio O, Nardelli S, Gioia S, Lucidi C, Merli M. Management of hepatic encephalopathy as an inpatient. Clinical Liver Disease. 2015;5(3):79–82. This paper could be useful to guide physicians in differential diagnosis of HECrossRef
4.
Zurück zum Zitat Pantham G, Mullen KD. Practical issues in the management of overt hepatic encephalopathy. Gastroenterol Hepatol (N Y). 2017;13(11):659–65.PubMedCentral Pantham G, Mullen KD. Practical issues in the management of overt hepatic encephalopathy. Gastroenterol Hepatol (N Y). 2017;13(11):659–65.PubMedCentral
5.
Zurück zum Zitat Simón-Talero M, García-Martínez R, Torrens M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013;59:1184–92.PubMedCrossRef Simón-Talero M, García-Martínez R, Torrens M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013;59:1184–92.PubMedCrossRef
6.
Zurück zum Zitat Sharma BC, Singh J, Srivastava S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol. 2017;32:1234–9.PubMedCrossRef Sharma BC, Singh J, Srivastava S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol. 2017;32:1234–9.PubMedCrossRef
7.
Zurück zum Zitat Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108:1458–63.PubMedCrossRef Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108:1458–63.PubMedCrossRef
8.
Zurück zum Zitat Rahimi RS, Singal AG, Cuthbert JA, et al. Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174:1727–33.PubMedPubMedCentralCrossRef Rahimi RS, Singal AG, Cuthbert JA, et al. Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174:1727–33.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat •• Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017;66:1727–38. This study is very interesting because it demonstrated for the first time the efficacy of fecal microbiota transplant in the treatment of HEPubMedCrossRef •• Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017;66:1727–38. This study is very interesting because it demonstrated for the first time the efficacy of fecal microbiota transplant in the treatment of HEPubMedCrossRef
11.
Zurück zum Zitat Schmidt L, Gørtz S, Wohlfahrt J, Melbye M, Munch TN. Recurrence of subdural haematoma in a population-based cohort—risks and predictive factors. PLoS One. 2015;10(10):e0140450.PubMedPubMedCentralCrossRef Schmidt L, Gørtz S, Wohlfahrt J, Melbye M, Munch TN. Recurrence of subdural haematoma in a population-based cohort—risks and predictive factors. PLoS One. 2015;10(10):e0140450.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Donovan LM, Kress WL, Strnad LC, et al. Low likelihood of intracranial hemorrhage in patients with cirrhosis and altered mental status. Clin Gastroenterol Hepatol. 2015;13(1):165–9.PubMedCrossRef Donovan LM, Kress WL, Strnad LC, et al. Low likelihood of intracranial hemorrhage in patients with cirrhosis and altered mental status. Clin Gastroenterol Hepatol. 2015;13(1):165–9.PubMedCrossRef
13.
Zurück zum Zitat Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137(3):885–91. 891 Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137(3):885–91. 891
14.
Zurück zum Zitat Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.PubMedCrossRef Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.PubMedCrossRef
15.
Zurück zum Zitat • Riggio O, Efrati C, Catalano C, Pediconi F, Mecarelli O, Accornero N, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology. 2005;42(5):1158–65. This study demonstrated that in patients with recurrent HE, there is a high prevalence of large porto systemic shunts that need to be searched by a CT scanPubMedCrossRef • Riggio O, Efrati C, Catalano C, Pediconi F, Mecarelli O, Accornero N, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology. 2005;42(5):1158–65. This study demonstrated that in patients with recurrent HE, there is a high prevalence of large porto systemic shunts that need to be searched by a CT scanPubMedCrossRef
16.
Zurück zum Zitat Ohnishi K, Sato S, Saito M, Terabayashi H, Nakayama T, Saito M, et al. Clinical and hemodynamic features in cirrhotic patients having a large spontaneous splenorenal and/or gastrorenal shunt. Am J Gastroenterol. 1986;81:450–5.PubMed Ohnishi K, Sato S, Saito M, Terabayashi H, Nakayama T, Saito M, et al. Clinical and hemodynamic features in cirrhotic patients having a large spontaneous splenorenal and/or gastrorenal shunt. Am J Gastroenterol. 1986;81:450–5.PubMed
17.
Zurück zum Zitat Simón-Talero M, Roccarina D, Martínez J, Lampichler K, Baiges A, Low G, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology. 2018 Jan 20. pii: S0016-5085(18)30069-6. Simón-Talero M, Roccarina D, Martínez J, Lampichler K, Baiges A, Low G, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology. 2018 Jan 20. pii: S0016-5085(18)30069-6.
19.
Zurück zum Zitat Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–75.PubMedCrossRef Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–75.PubMedCrossRef
20.
Zurück zum Zitat Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012 Feb;16(1):133–46.PubMedCrossRef Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012 Feb;16(1):133–46.PubMedCrossRef
21.
Zurück zum Zitat Kochar N, Tripathi D, Ireland H, et al. Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut. 2006;55:617–23.CrossRef Kochar N, Tripathi D, Ireland H, et al. Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut. 2006;55:617–23.CrossRef
22.
Zurück zum Zitat Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46.PubMedCrossRef Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46.PubMedCrossRef
23.
Zurück zum Zitat Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, et al. EASL-CLIF-Consortium. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57(6):2448–57.PubMedCrossRef Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, et al. EASL-CLIF-Consortium. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57(6):2448–57.PubMedCrossRef
24.
Zurück zum Zitat An J, Kim KW, Han S, et al. Improvment in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014;39(12):1418–26.PubMedCrossRef An J, Kim KW, Han S, et al. Improvment in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014;39(12):1418–26.PubMedCrossRef
25.
Zurück zum Zitat Gwon D, Kim Y, Ko G, Kim J, Ko H, Kim J, et al. Vascular plug-assisted retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy: a prospective multicenter study. J Vasc Interv Radiol. 2015;26:1589–95.PubMedCrossRef Gwon D, Kim Y, Ko G, Kim J, Ko H, Kim J, et al. Vascular plug-assisted retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy: a prospective multicenter study. J Vasc Interv Radiol. 2015;26:1589–95.PubMedCrossRef
26.
Zurück zum Zitat Mukund A, Deogaonkar G, Rajesh S, et al. Safety and Efficacy of Sodium Tetradecyl Sulfate and Lipiodol Foam in Balloon-OccludedRetrograde Transvenous Obliteration (BRTO) for Large Porto-Systemic Shunts. Cardiovasc Intervent Radiol. 2017;40(7):1010–6.PubMedCrossRef Mukund A, Deogaonkar G, Rajesh S, et al. Safety and Efficacy of Sodium Tetradecyl Sulfate and Lipiodol Foam in Balloon-OccludedRetrograde Transvenous Obliteration (BRTO) for Large Porto-Systemic Shunts. Cardiovasc Intervent Radiol. 2017;40(7):1010–6.PubMedCrossRef
27.
Zurück zum Zitat Bureau C, Thabut D, Oberti F, et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology. 2017 Jan;152(1):157–63.PubMedCrossRef Bureau C, Thabut D, Oberti F, et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology. 2017 Jan;152(1):157–63.PubMedCrossRef
28.
Zurück zum Zitat De Santis A, Nardelli S, Bassanelli C, et al. The modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol. 2017. De Santis A, Nardelli S, Bassanelli C, et al. The modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol. 2017.
29.
Zurück zum Zitat Nardelli S, Gioia S, Pasquale C, et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2016;111(4):523–8.PubMedCrossRef Nardelli S, Gioia S, Pasquale C, et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2016;111(4):523–8.PubMedCrossRef
30.
Zurück zum Zitat Cookson DT, Zaman Z, Gordon-Smith J, et al. Management of transjugular intrahepatic portosystemic shunt (TIPS)-associated refractory hepatic encephalopathy by shunt reduction using the parallel technique: outcomes of a retrospective case series. Cardiovasc Intervent Radiol. 2011;34:92–9.PubMedCrossRef Cookson DT, Zaman Z, Gordon-Smith J, et al. Management of transjugular intrahepatic portosystemic shunt (TIPS)-associated refractory hepatic encephalopathy by shunt reduction using the parallel technique: outcomes of a retrospective case series. Cardiovasc Intervent Radiol. 2011;34:92–9.PubMedCrossRef
31.
Zurück zum Zitat Fanelli F, Salvatori FM, Rabuffi P, et al. Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. Am J Roentgenol. 2009;193:1696–702.CrossRef Fanelli F, Salvatori FM, Rabuffi P, et al. Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. Am J Roentgenol. 2009;193:1696–702.CrossRef
Metadaten
Titel
Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments
verfasst von
Silvia Nardelli, MD
Lorenzo Ridola, MD, PhD
Stefania Gioia, MD
Oliviero Riggio, Prof, MD, PhD
Publikationsdatum
28.04.2018
Verlag
Springer US
Erschienen in
Current Treatment Options in Gastroenterology / Ausgabe 2/2018
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-018-0183-1

Weitere Artikel der Ausgabe 2/2018

Current Treatment Options in Gastroenterology 2/2018 Zur Ausgabe

Liver (J Bajaj, Section Editor)

Frailty in Patients With Cirrhosis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.